Clinical Trial Update: The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

The document reports an ongoing Phase 2 clinical trial evaluating irinotecan plus epirubicin as second-line chemotherapy for advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Epirubicin (epirubicin)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Anhui Medical University | Conditions: Stage IV Gastric Cancer With Metastasis | Phase 2 | Status: UNKNOWN